TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline
LEXINGTON, Mass.–(BUSINESS WIRE)–TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced the successful closing of its…